Introduction
PT. Indofarma (Persero) Tbk. (INAF),
operated as a State-Owned
Enterprises (SOEs) that produce
medicines and health products.
INAF products are marketed both
domestically and internationally.
INAF manufactures and distributes
pharmaceutical products, including
ethical and OTC products. INAF also
markets and distributes health
products. INAF ethical products
include generic drugs and branded
drugs, while OTC products are
classified into: OTC drugs, herbal
medicines and

Vision and Missions .

launched 22 new product items. both at schools and universities to conduct industrial working practices. Indofarma (Persero) Tbk producing generic drugs bearing (OGB). cooperates with medical devices principals to place the devices in hospitals. one of which is the OND .Indofarma (Persero) Tbk. Began to expand the target market by producing branded generic drugs or generic drugs under the trade name at an affordable price. licenses. • PT. Tbk. • PT.• PT Indofarma formerly the State Owned Enterprises (SOEs) and in 2001 began to go public • PT Indofarma contributing role in the field of education and providing opportunities to the pharmacy staff / analysts. The rest is OGB (generic drugs bearing) and 12 items Indo Drug Assault which is a product of OTC (Over The Counter) typical Indofarma • the Company through its Subsbidiary. • In 2007. PT Indofarma (Persero). This system is being managed under profit-sharing agreement between hospital. which is a government program for the supply of medicines to the public. trade names. IGM. . traditional medicine and medicinal trademark..

Ethical Products (OGB. Licenses.Products of PT. Indofarma 1. Trade Name) .

.

.

.

.

.

Source : Indofarma-AnnualReport-2014 .

.

.

.

SWOT Analysis Strength .

Liquidity .

Solvability .

ACCOUNT RECEIVABLES COLLECTIBILITY .

but the growth is still far behind compared to other companies • Several products were agreed by the decision makers to not being produced due to negative margin contribution are not included to the sales forecast. Indofarma is improving. PT. based on the solvability and liquidity ratio. companies should make a plan to improve the expertise to create a new drugs (for generic) with low cost but improving the quality of the product. • Improve other herbal Production • Based on the Financial condition. • Make more OND Product in order to decreasing the dependencies of selling generic brand • Make a huge promotion about launching the new product. .Company Recomendation • Based on the current condition.

co.co m/upload/bedrijfsprofiel/2018/Indof arma-Annual-Report-2014-Company-Pro file-INAF-Indonesia-Investments.indonesia-investments.pdf • http://www.bisnis.• http://bigcms.pdf • Indonesia adalah pasar yang besar bagi industri farmasi.com/file-data/ 1/1419/0e4a11f8_Des15-Indofarma(per sero)Tbk.blogspot. • http://yunitaardha.id/20 .